Genmab A/S (GMAB) Stock

Media Release COPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will take part in a fireside chat at Citi's 2024 Global Healthcare Conference on December 3 , 202 4 at 8 :30 PM CET / 2 : 30 P M EST. A webcast of the event will be available on Genmab's website at https://ir.genmab.com/events-presentations.

Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Jonathan Chang - LeeRink Partners Paul Jeng - Guggenheim Securities, LLC Zain Ebrahim - JPMorgan Chase Suzanne van Voorthuizen - Kempen & Co. Xian Deng - UBS Yaron Werber - TD Securities Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Matthew Phipps - William Blair Alistair Campbell - RBC Capital Markets Vikram Purohit - Morgan Stanley Etzer Darout - BMO Capital Markets Operator Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy Genmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab Genmab revenue increased 29% compared to the first nine months of 2023, to DKK 15,085 million Genmab 2024 financial guidance updated “The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious diseases. The additional approval for TEPKINLY, along with positive data presentations for our promising late-stage assets acasunlimab and rinatabart sesutecan (Rina-S), underscore the potential of our pipeline and our commitment to the development of innovative antibody-based therapeutics,” said Jan van de Winkel, Ph.D.

Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab's pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition.

Media Release COPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief Executive Officer , Jan van de Winkel, Ph.D. and C hief F inancial O fficer , Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 1 9 , 202 4 at 4:30 PM CET / 10 : 30 AM EST.

Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world.

Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents investors with the better value opportunity right now?